Apr 22 |
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
|
Apr 17 |
Scotiabank upgrades Legend Biotech to sector outperform
|
Apr 17 |
Analyst Ratings For Legend Biotech
|
Apr 11 |
Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
|
Apr 8 |
FDA Expands J&J's (JNJ) Carvykti Label in Multiple Myeloma
|
Apr 8 |
Why Legend Biotech (LEGN) Stock Might be a Great Pick
|
Apr 6 |
Johnson & Johnson wins FDA nod for Carvykti label expansion
|
Apr 6 |
Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
|
Apr 3 |
Should You Continue to Hold Legend Biotech Corporation (LEGN)?
|
Mar 29 |
Management’s Conservative Guidance Led Legend Biotech Corporation (LEGN) to Decline in Q4
|